Press Releases

Press Releases

September 6, 2017
Appoints Canadian General Manager CAMBRIDGE, Mass. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid
September 5, 2017
Expansion of Akcea Leadership Further Strengthens Financial, Clinical and Commercial Foundation CAMBRIDGE, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. focused on developing and commercializing drugs to treat patients
August 31, 2017
CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced
August 29, 2017
CAMBRIDGE, Mass. , Aug. 29, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that
August 8, 2017
Marketing authorization application submitted to the European Medicines Agency for the approval of volanesorsen Cash balance of approximately $300 million to fund volanesorsen launch and cardiometabolic pipeline advancement Strategic investment of $75 million by Novartis and Ionis   CAMBRIDGE,
July 27, 2017
CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for volanesorsen
July 19, 2017
CAMBRIDGE, Mass. , July 19, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the closing of its initial public offering of 17,968,750 shares common stock at a public offering price of $8.00 per share, including 2,343,750 shares of common stock issued upon full exercise by the
July 13, 2017
CAMBRIDGE, Mass. , July 13, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the pricing of its initial public offering of 15,625,000 shares common stock at a public offering price of $8.00 per share, for gross proceeds of $125.0 million before underwriting discounts and commissions
June 20, 2017
CAMBRIDGE, Mass. , June 20, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced that it has launched the proposed initial public offering of its common stock. Akcea is offering 9,620,000 shares of common stock and the underwriters will have a 30-day option to purchase up to an additional
May 25, 2017
CAMBRIDGE, Mass., May 25, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the publication in  The New England Journal of Medicine  of key preclinical findings with angiopoietin-like